RESUMEN
OBJECTIVE: Presentation of a case report and pharmacokinetic investigation in healthy volunteers on the potential interference between cardiac glycosides and glycosides of Uzara, a herbal antidiarrheal preparation. METHODS: Pharmacokinetic pilot investigation of apparent digitoxin and digoxin serum concentrations in 4 healthy volunteers after single-dose administration of 30 drops Uzara (approximately 1.5 ml approximately = 22 mg glycosides). RESULTS: Maximal apparent serum concentrations of digitoxin between 198.0 microg/l and 919.8 microg/l (therapeutic range: 10-25 microg/l) occurred at 4-8 hours after administration. The terminal half-life of the glycosides was 8.87 +/- 2.20 hours. For digoxin, maximal apparent serum concentrations ranged between 1.4 microg/l and 6.34 microg/l (therapeutic range: 0.9-2.0 microg/l) at 6 hours post dosing. CONCLUSIONS: Administration of a single dose of an Uzara preparation, an over-the-counter product, results in false high serum concentrations of digitoxin and digoxin. As described in the manufacturers Summary of Product Characteristics, this preparation should not be given to patients with cardiac failure or arrhythmia who require treatment with cardiac glycosides because of the demonstrated pharmacological actions of uzara glycosides.
Asunto(s)
Antiarrítmicos/sangre , Antidiarreicos/sangre , Apocynaceae/química , Glicósidos/sangre , Adulto , Anciano , Digitoxina/sangre , Digoxina/sangre , Reacciones Falso Positivas , Femenino , Semivida , Interacciones de Hierba-Droga , Humanos , Masculino , Proyectos Piloto , Extractos Vegetales/sangre , Raíces de Plantas/químicaRESUMEN
BACKGROUND: Digitoxin and valproic acid show strong binding to serum albumin. Thus, when present simultaneously in serum, digitoxin and valproic acid compete for binding sites. We studied digitoxin-valproic acid interaction in normal and uremic sera. METHODS: Fluorescence polarization immunoassays were used for measuring total digitoxin and total valproic acid concentrations. We used a modified protocol of improved sensitivity to measure free digitoxin concentrations. We supplemented 2 normal and 2 uremic pools with digitoxin and then aliquots of these pools were further supplemented with various concentrations of valproic acid. After incubation at 37 degrees C for 2 hours in a water bath, specimens were allowed to re-equilibrate at room temperature for 20 minutes. Free digitoxin concentrations were measured. We also investigated digoxin-valproic acid interaction using 1 normal and 1 uremic serum pool. RESULTS: We observed significant increases in free digitoxin concentrations in normal sera in the presence of valproic acid. In contrast, we observed a slight decline in free digitoxin concentration in the presence of valproic acid in uremic sera. We speculated that uremic sera contained inhibitors that block digitoxin-valproic acid interaction and identified indoxyl sulfate as an inhibitor. However, another uremic compound, hippuric acid showed no inhibitory effect. Interestingly, we observed no significant interaction between digoxin and valproic acid in either normal or uremic serum pool. This is probably because of poor protein binding of digoxin. CONCLUSION: We conclude that valproic acid significantly displaces digitoxin from protein binding sites in normal serum. However, uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
Asunto(s)
Digitoxina/antagonistas & inhibidores , Digitoxina/sangre , Uremia/sangre , Ácido Valproico/antagonistas & inhibidores , Ácido Valproico/sangre , Anticonvulsivantes/antagonistas & inhibidores , Anticonvulsivantes/sangre , Sitios de Unión , Unión Competitiva , Cardiotónicos/antagonistas & inhibidores , Cardiotónicos/sangre , Interacciones Farmacológicas , Hipuratos/sangre , Hipuratos/farmacología , Humanos , Técnicas In Vitro , Indicán/sangre , Indicán/farmacología , Unión Proteica , Albúmina Sérica/metabolismo , Uremia/tratamiento farmacológicoRESUMEN
A 22-year-old man presented to our emergency department after an intentional overdose of a homemade foxglove extract. Clinical symptoms with symptomatic bradyarrhythmia and ECG changes were consistent with cardiac glycoside poisoning. Treatment with digoxin-specific Fab fragments resulted in transient clinical and ECG improvement. Serum immunoassay demonstrated a digitoxin-like glycoside. The serum levels showed no evidence of altered elimination or distribution with Fab therapy despite temporary improvements in the clinical course. The use of Fab did not result in a shortened clinical course in this episode of foxglove poisoning, as one would expect in the setting of commercial glycoside product poisoning.
Asunto(s)
Digitalis , Digoxina/inmunología , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Plantas Medicinales , Plantas Tóxicas , Intoxicación/terapia , Adulto , Digitoxina/sangre , Semivida , Humanos , Fragmentos Fab de Inmunoglobulinas/metabolismo , Masculino , Extractos Vegetales/envenenamiento , Intento de SuicidioRESUMEN
A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Blood and urine samples were collected over a 98 h period for monitoring the efficacy and adequacy of FAB treatment. DGTX concentrations were determined after protein precipitation (release of FAB-bound and protein-bound DGTX) in unprocessed serum and urine samples, and after aliquots of these samples had been dialysed in vitro against DGTX-free buffer (elimination of DGTX not bound to FAB). The difference in DGTX concentration between the unprocessed and dialysed samples was the amount of DGTX bound to plasma proteins and the small fraction of unbound DGTX being relevant for the therapeutic and toxic effects of the drug. Before FAB therapy was started, the total serum DGTX concentration was 535 nmol/l. The first FAB infusion (320 mg) was started 11 h after drug ingestion. Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted. During a second FAB infusion (400 mg) the patient reverted to regular AV-conduction. At this time most of the DGTX in serum was FAB-bound. Toxic symptoms (sinus arrest) reappeared twice and were accompanied by increasing amounts of non-antibody-bound DGTX in the serum. Additional application of FAB (2 x 80 mg) resulted in the immediate disappearance of arrhythmia. During FAB-treatment total DGTX serum concentrations and renal DGTX clearance rose, indicating redistribution of drug from tissue to serum and urinary elimination of FAB-bound DGTX, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Anticuerpos Antiidiotipos/uso terapéutico , Digitalis/inmunología , Digitoxina/envenenamiento , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Plantas Medicinales , Plantas Tóxicas , Intoxicación/tratamiento farmacológico , Adulto , Anticuerpos Antiidiotipos/administración & dosificación , Digitoxina/sangre , Digitoxina/orina , Electroforesis en Gel de Poliacrilamida , Humanos , Fragmentos Fab de Inmunoglobulinas/administración & dosificación , Fragmentos Fab de Inmunoglobulinas/orina , Infusiones Intravenosas , Masculino , Tasa de Depuración Metabólica , Intoxicación/sangre , Intoxicación/orina , Intento de SuicidioRESUMEN
The influence of two progestins, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), given orally in high doses, on the pharmacokinetics of antipyrine, digitoxin, and warfarin were studied in patients with advanced breast cancer. Antipyrine and warfarin were given as a single test dose before and after 5 weeks of progestin treatment. The pharmacokinetics of digitoxin was investigated at steady state in patients receiving this drug therapeutically before and during treatment with progestins. Small changes in clearance rates for antipyrine, warfarin, and digitoxin were found. A minor decrease observed in warfarin clearance however may be of clinical importance. Half-lives decreased by 13% for antipyrine and increased by 71% for warfarin. High-dose progestins given orally do not seem to have a major influence on drug metabolism, probably reflecting a minor effect on drug and steroid-metabolizing microsomal mono-oxygenases in the liver.
Asunto(s)
Antipirina/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Digitoxina/metabolismo , Congéneres de la Progesterona/farmacología , Warfarina/metabolismo , Administración Oral , Anciano , Anciano de 80 o más Años , Antipirina/sangre , Neoplasias de la Mama/metabolismo , Digitoxina/sangre , Femenino , Humanos , Cinética , Masculino , Medroxiprogesterona/administración & dosificación , Medroxiprogesterona/análogos & derivados , Medroxiprogesterona/farmacología , Medroxiprogesterona/uso terapéutico , Acetato de Medroxiprogesterona , Megestrol/administración & dosificación , Megestrol/análogos & derivados , Megestrol/farmacología , Megestrol/uso terapéutico , Acetato de Megestrol , Persona de Mediana Edad , Congéneres de la Progesterona/administración & dosificación , Congéneres de la Progesterona/uso terapéutico , Warfarina/sangreRESUMEN
To determine whether verapamil, diltiazem, or nifedipine affect digitoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during steady-state dosing in 30 patients with cardiac insufficiency. The mean (+/- SD) digitoxin plasma concentration was 14.27 +/- 3.66 ng/ml before and 18.15 +/- 5.33 ng/ml during verapamil dosing in 10 patients over a period of 4 to 6 weeks. Renal digitoxin clearance was not influenced by verapamil, but total body clearance and extrarenal clearance of digitoxin were reduced by 27% and 29%, respectively. Diltiazem resulted in a 6% to 31% (mean = 21%) increase in plasma digitoxin concentrations in five of 10 patients because of reduced extrarenal clearance of digitoxin. In contrast to verapamil, the concomitant dosing of nifedipine over 4 to 6 weeks did not alter digitoxin plasma levels or daily renal excretion. Based on these observations, the risk of digitalis intoxication after combined dosing with verapamil and digitoxin is much less pronounced than that after digoxin, and thus this glycoside is a valuable alternative.